SCHEMBL17858734

SCHEMBL17858734

Cc1cncc(-c2cc(O)n[nH]2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 3/20 0.39
CYP2A6 P11509 3/20 0.39
KIT P10721 1/20 0.38
MEN1 O00255 4/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
KMT2A Q03164 4/20 0.37
CDK7 P50613 1/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HCAR2 Q8TDS4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13886508 0.81 SMN1; SMN2 (0.40) TNIKMEN1NPC1RAB9AKMT2A
SCHEMBL1858951 0.79 SMN1; SMN2 (0.61) TNIKCYP2A6KITMEN1NPC1
SCHEMBL19737073 0.78 PRMT5 (0.40) TNIKCYP2A6NPC1RAB9ACYP11B1
SCHEMBL19736896 0.78 KMT2A (0.41) TNIKMEN1NPC1RAB9AKMT2A
SCHEMBL17858741 0.76 NPC1 (0.49) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL18218782 0.76 SMN1; SMN2 (0.61) TNIKMEN1NPC1RAB9AKMT2A
SCHEMBL18122018 0.73 RAB9A (0.64) NPC1RAB9ACYP11B1CYP11B2ALDH1A1
SCHEMBL3423606 0.71 CYP2A6 (0.61) CYP2A6CYP11B1CYP11B2PRMT5WDR77
SCHEMBL7998222 0.69 PDPK1 (0.47) TNIKRAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL29806349 0.69 CYP2A6 (0.55) CYP2A6NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-12-21 US disclosed
WO-2016100347-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 TNIK 224/4885CYP2A6 3614/4885KIT 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.